Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3.

Cancer Prevention Research
Alpna TyagiRajesh Agarwal

Abstract

The latency period for lung tumor progression offers a window of opportunity for therapeutic intervention. Herein, we studied the effect of oral silibinin (742 mg/kg body weight, 5 d/wk for 10 weeks) on the growth and progression of established lung adenocarcinomas in A/J mice. Silibinin strongly decreased both tumor number and tumor size, an antitumor effect that correlates with reduced antiangiogenic activity. Silibinin reduced microvessel size (50%, P < 0.01) with no change in the number of tumor microvessels and reduced (by 30%, P < 0.05) the formation of nestin-positive microvessels in tumors. Analysis of several proteins involved in new blood vessel formation showed that silibinin decreased the tumor expression of interleukin-13 (47%) and tumor necrosis factor-alpha (47%), and increased tissue inhibitor of metalloproteinase-1 (2-fold) and tissue inhibitor of metalloproteinase-2 (7-fold) expression, without significant changes in vascular endothelial growth factor levels. Hypoxia- inducible factor-1 alpha expression and nuclear localization were also decreased by silibinin treatment. Cytokines secreted by tumor cells and tumor-associated macrophages regulate angiogenesis by activating nuclear factor-kappaB (NF-kappaB) and ...Continue Reading

References

May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M YouM W Anderson
Jun 8, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A M Malkinson
May 29, 2003·Current Cancer Drug Targets·Rana P Singh, Rajesh Agarwal
Jan 8, 2004·Seminars in Thoracic and Cardiovascular Surgery·Daniel D KarpEdward S Kim
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rana P SinghRajesh Agarwal
Feb 25, 2005·International Journal of Cancer. Journal International Du Cancer·Madeleine M Handsley, Dylan R Edwards
Sep 20, 2005·Chemico-biological Interactions·Pei-Ni ChenShu-Chen Chu
Jan 18, 2006·Annual Review of Medicine·Judah Folkman
Apr 26, 2006·Molecular Carcinogenesis·Rana P Singh, Rajesh Agarwal
Jun 22, 2006·Journal of the National Cancer Institute·Rana P SinghRajesh Agarwal
Oct 19, 2006·Pharmacology & Therapeutics·KangAe LeeJohn J LaPres
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carter Van Waes
Aug 19, 2007·Cancer Research·Xiao-Feng LiJoseph A O'Donoghue
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Georgios T StathopoulosTimothy S Blackwell
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Oct 18, 2013·Cancer Immunology, Immunotherapy : CII·Matteo SantoniStefano Cascinu
Aug 10, 2010·Parasitology Research·Hílton Antonio Mata-SantosAlexandre dos Santos Pyrrho
May 5, 2012·Apoptosis : an International Journal on Programmed Cell Death·Henriette KauntzFrancis Raul
Aug 18, 2010·Cancer Metastasis Reviews·Gagan Deep, Rajesh Agarwal
Sep 26, 2009·Pharmaceutical Research·Subapriya RajamanickamRajesh Agarwal
Jun 25, 2009·Nature Reviews. Cancer·Stephen S HechtDorothy K Hatsukami
Mar 11, 2010·Cancer Research·Subapriya RajamanickamRajesh Agarwal
Dec 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kumaraguruparan RamasamyRajesh Agarwal
Oct 4, 2013·Immunotherapy·Roheena Z PanniDavid G DeNardo
Jun 6, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Mengzhu XueHonglin Li
Jan 6, 2010·Expert Opinion on Investigational Drugs·Lei LiDalin He
May 3, 2016·Current Pharmacology Reports·Jay MorrisMichael J Wargovich
Dec 14, 2011·Clinical & Developmental Immunology·Marc BaayFilip Lardon
Sep 26, 2009·Biochemical and Biophysical Research Communications·Hui-Jung JungWon-Ki Baek
Dec 10, 2009·Molecular Aspects of Medicine·Danielle Park, Pierre J Dilda
Jan 21, 2015·Seminars in Cancer Biology·Zongwei WangLasse D Jensen
Jul 23, 2011·Apoptosis : an International Journal on Programmed Cell Death·Henriette KauntzFrancis Raul
Jan 6, 2012·Neurochemical Research·Yongwei QinChun Cheng
Jan 13, 2015·Homeopathy : the Journal of the Faculty of Homeopathy·Oguz MutluFaruk Erden
Sep 29, 2019·Advanced Materials·Meilyn SylvestreSuzie H Pun
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Ashok Kumar Pandurangan, Norhaizan Mohd Esa
Mar 20, 2015·Phytotherapy Research : PTR·Niroshaathevi ArumuggamH P Vasantha Rupasinghe
Sep 28, 2017·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Alexandra K TsarouchaConstantinos E Simopoulos
Nov 30, 2016·BioFactors·Saeideh MomtazSeyed Mohammad Nabavi
Nov 2, 2012·Immunology·Xiaoqiang TangHengyi Xiao
Feb 2, 2016·Homeopathy : the Journal of the Faculty of Homeopathy·Oguz MutluFaruk Erden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.